DK3746437T3 - MKK4-proteinkinaseinhibitorer til at fremme leverregenerering eller reducere eller forebygge hepatocytdød - Google Patents
MKK4-proteinkinaseinhibitorer til at fremme leverregenerering eller reducere eller forebygge hepatocytdød Download PDFInfo
- Publication number
- DK3746437T3 DK3746437T3 DK19701674.4T DK19701674T DK3746437T3 DK 3746437 T3 DK3746437 T3 DK 3746437T3 DK 19701674 T DK19701674 T DK 19701674T DK 3746437 T3 DK3746437 T3 DK 3746437T3
- Authority
- DK
- Denmark
- Prior art keywords
- reduce
- protein kinase
- kinase inhibitors
- liver regeneration
- promote liver
- Prior art date
Links
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 title 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 210000003494 hepatocyte Anatomy 0.000 title 1
- 210000004185 liver Anatomy 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 230000008929 regeneration Effects 0.000 title 1
- 238000011069 regeneration method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154454 | 2018-01-31 | ||
| EP18183692 | 2018-07-16 | ||
| PCT/EP2019/052213 WO2019149738A1 (en) | 2018-01-31 | 2019-01-30 | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3746437T3 true DK3746437T3 (da) | 2024-11-11 |
Family
ID=65228576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19701674.4T DK3746437T3 (da) | 2018-01-31 | 2019-01-30 | MKK4-proteinkinaseinhibitorer til at fremme leverregenerering eller reducere eller forebygge hepatocytdød |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11858927B2 (da) |
| EP (1) | EP3746437B1 (da) |
| JP (1) | JP7337813B2 (da) |
| KR (1) | KR102834253B1 (da) |
| CN (1) | CN111788195B (da) |
| AU (1) | AU2019216264B2 (da) |
| BR (1) | BR112020015072A2 (da) |
| CA (1) | CA3089678A1 (da) |
| DK (1) | DK3746437T3 (da) |
| ES (1) | ES3000465T3 (da) |
| FI (1) | FI3746437T3 (da) |
| HR (1) | HRP20241555T1 (da) |
| HU (1) | HUE069545T2 (da) |
| IL (1) | IL276353B2 (da) |
| MA (1) | MA51889A (da) |
| MX (1) | MX2020007954A (da) |
| PL (1) | PL3746437T3 (da) |
| SG (1) | SG11202007143UA (da) |
| WO (1) | WO2019149738A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3746437T3 (da) | 2018-01-31 | 2024-11-11 | Heparegenix Gmbh | MKK4-proteinkinaseinhibitorer til at fremme leverregenerering eller reducere eller forebygge hepatocytdød |
| US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| BR112020026003A2 (pt) | 2018-07-16 | 2021-03-23 | Heparegenix Gmbh | inibidores de proteína quinase para promover a regeneração do fígado ou reduzir ou prevenir a morte de hepatócitos |
| WO2021018820A1 (en) * | 2019-07-29 | 2021-02-04 | Heparegenix Gmbh | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| AU2021207236A1 (en) * | 2020-01-15 | 2022-08-11 | Heparegenix Gmbh | 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as MKK4 inhibitors for treating liver diseases |
| CN111423443A (zh) * | 2020-04-03 | 2020-07-17 | 广州科锐特生物科技有限公司 | 一种4-氨基-7-碘吡咯并[2,1-f][1,2,4]三嗪的制备方法 |
| WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
| JP2023536814A (ja) * | 2020-07-30 | 2023-08-30 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 細胞の増殖を刺激する方法 |
| CN112194661B (zh) * | 2020-10-22 | 2021-06-08 | 威海同丰海洋生物科技有限公司 | 一种4-氨基-7-碘吡咯并[2,l-f][l,2,4]三嗪的制备方法 |
| US20240174683A1 (en) | 2021-02-05 | 2024-05-30 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
| EP4504185A1 (en) | 2022-04-06 | 2025-02-12 | HepaRegeniX GmbH | Pharmaceutical composition for the treatment of colon and lung cancer |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514981B1 (en) | 1998-04-02 | 2003-02-04 | Sugen, Inc. | Methods of modulating tyrosine protein kinase function with indolinone compounds |
| CA2464214C (en) | 2001-10-22 | 2011-02-08 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
| WO2003037898A1 (en) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Pyrimido [4,5-b] indole derivatives |
| AU2003300522A1 (en) | 2002-12-27 | 2004-07-22 | Bayer Healthcare Ag | 4-phenyl-pyrimido (4,5-b) indole derivatives |
| FR2876377B1 (fr) | 2004-10-11 | 2007-03-16 | Univ Claude Bernard Lyon | Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes |
| JP2006282745A (ja) | 2005-03-31 | 2006-10-19 | Fuji Photo Film Co Ltd | セルロース誘導体組成物、セルロース誘導体フィルム、および置換安息香酸誘導体化合物 |
| MX2007014377A (es) | 2005-05-17 | 2008-02-06 | Plexxikon Inc | Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina. |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| EP2161271A1 (en) | 2008-09-08 | 2010-03-10 | Università Degli Studi Di Milano - Bicocca | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl |
| JP2012520307A (ja) | 2009-03-11 | 2012-09-06 | プレキシコン インコーポレーテッド | Ｒａｆキナーゼの阻害のためのピロロ［２，３−ｂ］ピリジン誘導体 |
| WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US9062076B2 (en) | 2009-10-22 | 2015-06-23 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| CN102753549A (zh) | 2009-12-23 | 2012-10-24 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
| SMT201900112T1 (it) | 2011-02-07 | 2019-02-28 | Plexxikon Inc | Composti e metodi per la modulazione della chinasi, e indicazioni corrispettive |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| US8791112B2 (en) | 2011-03-30 | 2014-07-29 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors |
| EP2508607A1 (en) * | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| CA2846574C (en) | 2011-08-26 | 2020-07-07 | Neupharma, Inc. | Quinoxaline sulfonamide derivates for use as kinase inhibitors |
| TWI601725B (zh) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
| US9688635B2 (en) | 2012-09-24 | 2017-06-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CA2912568A1 (en) | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| BR112017014341A2 (pt) | 2015-01-09 | 2018-03-27 | Gilead Apollo, Llc | método e sistema para tratamento, estabilização, ou redução da gravidade ou progressão de uma doença de fígado gorduroso não alcoólica, e, composição. |
| US9890163B2 (en) | 2015-10-15 | 2018-02-13 | Princeton Drug Discovery Inc | Inhibitors of protein kinases |
| AU2018209164B2 (en) | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| EP3666770A4 (en) | 2017-08-07 | 2021-04-07 | Joint Stock Company "Biocad" | NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS |
| DK3746437T3 (da) | 2018-01-31 | 2024-11-11 | Heparegenix Gmbh | MKK4-proteinkinaseinhibitorer til at fremme leverregenerering eller reducere eller forebygge hepatocytdød |
| RU2678455C1 (ru) * | 2018-06-01 | 2019-01-29 | Сергей Викторович Леонов | Кристаллическая форма n-(3-(5-(4-хлорофенил)-1н-пиразоло[3,4-в]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамида, активный компонент, фармацевтическая композиция и лекарственное средство |
| US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| BR112020026003A2 (pt) | 2018-07-16 | 2021-03-23 | Heparegenix Gmbh | inibidores de proteína quinase para promover a regeneração do fígado ou reduzir ou prevenir a morte de hepatócitos |
| EP3847159A2 (en) | 2018-09-04 | 2021-07-14 | Magenta Therapeutics, Inc. | Aryl hydrocarbon receptor antagonists and methods of use |
| US12098117B2 (en) | 2018-12-11 | 2024-09-24 | Duke University | Compositions and methods for the treatment of cancer |
| US11370770B2 (en) | 2019-06-24 | 2022-06-28 | Northwestern University | 3-arylindazoles as selective MEK4 inhibitors |
| WO2021018820A1 (en) | 2019-07-29 | 2021-02-04 | Heparegenix Gmbh | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN112778311B (zh) | 2019-11-01 | 2024-06-04 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂、其制备方法和应用 |
| AU2021207236A1 (en) | 2020-01-15 | 2022-08-11 | Heparegenix Gmbh | 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as MKK4 inhibitors for treating liver diseases |
| WO2022150962A1 (en) | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Protease inhibitors, preparation, and uses thereof |
-
2019
- 2019-01-30 DK DK19701674.4T patent/DK3746437T3/da active
- 2019-01-30 AU AU2019216264A patent/AU2019216264B2/en active Active
- 2019-01-30 HR HRP20241555TT patent/HRP20241555T1/hr unknown
- 2019-01-30 ES ES19701674T patent/ES3000465T3/es active Active
- 2019-01-30 CA CA3089678A patent/CA3089678A1/en active Pending
- 2019-01-30 FI FIEP19701674.4T patent/FI3746437T3/fi active
- 2019-01-30 JP JP2020540553A patent/JP7337813B2/ja active Active
- 2019-01-30 CN CN201980011310.4A patent/CN111788195B/zh active Active
- 2019-01-30 EP EP19701674.4A patent/EP3746437B1/en active Active
- 2019-01-30 IL IL276353A patent/IL276353B2/en unknown
- 2019-01-30 WO PCT/EP2019/052213 patent/WO2019149738A1/en not_active Ceased
- 2019-01-30 US US16/965,912 patent/US11858927B2/en active Active
- 2019-01-30 BR BR112020015072-0A patent/BR112020015072A2/pt unknown
- 2019-01-30 MA MA051889A patent/MA51889A/fr unknown
- 2019-01-30 PL PL19701674.4T patent/PL3746437T3/pl unknown
- 2019-01-30 MX MX2020007954A patent/MX2020007954A/es unknown
- 2019-01-30 HU HUE19701674A patent/HUE069545T2/hu unknown
- 2019-01-30 KR KR1020207021909A patent/KR102834253B1/ko active Active
- 2019-01-30 SG SG11202007143UA patent/SG11202007143UA/en unknown
-
2023
- 2023-11-08 US US18/388,084 patent/US12264158B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL276353B2 (en) | 2024-02-01 |
| JP2021514346A (ja) | 2021-06-10 |
| US12264158B2 (en) | 2025-04-01 |
| HRP20241555T1 (hr) | 2025-01-17 |
| US11858927B2 (en) | 2024-01-02 |
| US20210078995A1 (en) | 2021-03-18 |
| RU2020125133A3 (da) | 2022-02-28 |
| FI3746437T3 (fi) | 2024-11-21 |
| SG11202007143UA (en) | 2020-08-28 |
| MX2020007954A (es) | 2021-01-08 |
| EP3746437A1 (en) | 2020-12-09 |
| EP3746437B1 (en) | 2024-08-21 |
| KR102834253B1 (ko) | 2025-07-15 |
| IL276353A (en) | 2020-09-30 |
| PL3746437T3 (pl) | 2025-01-07 |
| AU2019216264A1 (en) | 2020-08-13 |
| IL276353B1 (en) | 2023-10-01 |
| ES3000465T3 (en) | 2025-02-28 |
| AU2019216264B2 (en) | 2023-08-31 |
| JP7337813B2 (ja) | 2023-09-04 |
| MA51889A (fr) | 2021-05-05 |
| US20240116931A1 (en) | 2024-04-11 |
| CN111788195B (zh) | 2023-11-21 |
| CN111788195A (zh) | 2020-10-16 |
| WO2019149738A1 (en) | 2019-08-08 |
| HUE069545T2 (hu) | 2025-03-28 |
| KR20200138166A (ko) | 2020-12-09 |
| RU2020125133A (ru) | 2022-02-28 |
| CA3089678A1 (en) | 2019-08-08 |
| BR112020015072A2 (pt) | 2021-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3746437T3 (da) | MKK4-proteinkinaseinhibitorer til at fremme leverregenerering eller reducere eller forebygge hepatocytdød | |
| ZA201905078B (en) | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| IL279641A (en) | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocytic death | |
| HUE062096T2 (hu) | Piridazinonok PARP7-inhibitorokként | |
| IL268895A (en) | Compositions and methods for inhibition of lineage specific proteins | |
| HUE062404T2 (hu) | Protein tirozin foszfatáz inhibitorok | |
| IL290190A (en) | Pyrazolopyridine-substituted heteroaryl protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| DK3244909T3 (da) | Proteasominhibitorer til at behandle en lidelse relateret til en akkumulering af ikke-degraderet unormalt protein eller en cancer | |
| DK3693158T3 (da) | Asymmetrisk forarbejdningsfremgangsmåde til krumningsreduktion i laminatstrukturer | |
| DK3322305T3 (da) | Anvendelse af peptidylarginin-deiminase til opløsning af proteiner, eventuelt yderligere til reducering af deres skumningstendens | |
| EP3697787A4 (en) | Heterocyclic compound as a protein kinase inhibitor | |
| EP3941922A4 (en) | Inhibitors of raf kinases | |
| IL281108A (en) | Compositions and methods for enhancing donor oligonucleotide-based gene editing | |
| DK3531866T3 (da) | Modulært dæksystem til anvendelse med bevægelige platforme | |
| EP3540433A4 (en) | SYSTEM FOR ESTIMATING THE CONCENTRATION OF AN INJECTION AGENT IN THE SOIL | |
| DK3288931T4 (da) | Visse proteinkinaseinhibitorer | |
| DK3554519T3 (da) | Bacillus-baserede komponenter til hæmning eller forsinkelse af væksen af enterococcus ssp. hos dyr | |
| DK3795995T3 (da) | Samtidig detektion af forbindelser, der er uhensigtsmæssige eller relateret til afsmag af svinekød i animalsk væv | |
| EP3640335A4 (en) | PLATFORM FOR EXPRESSING A PROTEIN OF INTEREST IN THE LIVER | |
| EP3638237A4 (en) | AMINOTHIAZOLIC COMPOUNDS USED AS PROTEIN KINASE INHIBITORS | |
| EP3555092A4 (en) | PROTEIN KINASE INHIBITORS | |
| HUE056875T2 (hu) | 5-lipoxigenáz-aktiváló protein (FLAP) inhibitorokként alkalmazható pirazol származékok | |
| EP3768266A4 (en) | OXO-TETRAHYDRO-ISOQUINOLINE CARBOXYLIC ACIDS AS STING PROTEIN INHIBITORS | |
| EP3715343A4 (en) | COMPOUND OF DIPHENYLAMINOPYRIMIDINE INHIBITING THE ACTIVITY OF KINASE | |
| DK3917538T3 (da) | Deoxycytidinderivater til anvendelse i cancerterapier |